D-0018-2021 Class II Terminated
FDA drug recall D-0018-2021 was initiated by Direct Rx on Apr 30, 2019 and is designated Class II. Reason for recall: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level per manufacturer The recall status is terminated (terminated Dec 4, 2020). Affected quantity: 33 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 14, 2020
- Initiation Date
- Apr 30, 2019
- Termination Date
- Dec 4, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 33 bottles
Product description
Losartan Potassium 100 mg, 30 Tabs bottles, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 NDC 61919-952-30
Reason for recall
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level per manufacturer
Distribution pattern
GA
Code information
Lot: 27AU1801 Exp. 02/28/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0018-2021
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026